Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Finasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 known ✓ | P31213 | 9/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 16/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | HSD3B1 | P14060 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Finasteride SCHEMBL1560981 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL5148287 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL11909 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL5509 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL13575812 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969512 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL3982016 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22032590 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22564355 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969513 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | claimed |
| EP-1523490-B1 | METHOD FOR INTRODUCING A 1,2 DOUBLE BOND INTO 3-OXO-4-AZASTEROID COMPOUNDS | SIEGFRIED GENERICS INT AG (CH) | 2009-12-23 | — | — | EP | claimed |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2006-05-11 | — | — | US | claimed |
| US-5547957-A | oral low daily dosage of FINASTERIDE; treating male pattern baldness; promoting hair growth; hyperandrogenic conditions of acne vulgaris, seborrhea, polycystic ovary syndrome, female hirsutism | MERCK & CO., INC. (US) | 1996-08-20 | — | — | US | claimed |
| EP-0155096-B1 | 17 BETA-SUBSTITUTED-4-AZA-5-ALPHA-ANDROSTENONES AND THEIR USE AS 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1989-10-04 | — | — | EP | claimed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | claimed |
| US-12029811-B2 | Formulation and method for the treatment of androgenic alopecia | CENTRO INTERNACIONAL DE COSMIATRÍA, S.A.P.I. DE C.V. (MX) | 2024-07-09 | — | — | US | disclosed |
| US-20210106519-A1 | FORMULATION AND METHOD FOR THE TREATMENT OF ANDROGENIC ALOPECIA | CENTRO INTERNACIONAL DE COSMIATRÍA, S.A.P.I. DE C.V. (MX) | 2021-04-15 | — | — | US | disclosed |
| EP-3750542-A1 | FORMULATION AND METHOD FOR THE TREATMENT OF ANDROGENIC ALOPECIA | Centro Internacional de Cosmiatría, S.A.P.I. de C.V. (MX) | 2020-12-16 | — | — | EP | disclosed |
| EP-1523490-B1 | METHOD FOR INTRODUCING A 1,2 DOUBLE BOND INTO 3-OXO-4-AZASTEROID COMPOUNDS | SIEGFRIED GENERICS INT AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| EP-1504021-B1 | PROCESS FOR DEHYDROGENATION OF AZAANDROSTANE COMPOUNDS | RICHTER GEDEON VEGYESZET (HU) | 2006-07-12 | — | — | EP | disclosed |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2006-05-11 | — | — | US | disclosed |
| US-6762302-B2 | DEPROTONATION OF AZASTEROIDS USING CULTURES OF BIOCATALYSTS, OXIDOREDUCTASE ENZYMES, STABILIZERS, COMPLEXING AGENTS AND CHARGE TRANSFER COMPOUNDS, THEN INCUBATING | GEDEON RICHTER, LTD. (HU) | 2004-07-13 | — | — | US | disclosed |
| US-20030215902-A1 | Process for dehydrogenation of azaandros tane compounds | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-11-20 | — | — | US | disclosed |
| EP-0674521-B1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17$g(b)-N-TERTBUTYLCARBAMOYL-4-AZA-5$g(a)-ANDROST-1-EN-3-ONE | MERCK & CO INC (US) | 2001-07-18 | — | — | EP | disclosed |
| US-5629318-A | Method of treatment of chronic prostatitis with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. (US) | 1997-05-13 | — | — | US | disclosed |
| US-5380728-A | Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a | MERCK & CO., INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0271220-B1 | OXIDIZED ANALOGS OF 17 BETA-N-MONOSUBSTITUTED CARBAMOYL-4-AZA 5 ALPHA-ANDROST-1-EN-3-ONES | MERCK & CO. INC. (US) | 1992-01-29 | — | — | EP | disclosed |
| US-4845104-A | Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones | MERCK & CO., INC. (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0271220-A1 | Oxidized analogs of 17 beta-N-monosubstituted carbamoyl-4-aza 5 alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | NR3C2, NR5A1, CYP11B1 | SRD5A2 7/4885SRD5A1 14/4885LMNA 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.